TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01125553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Each subject will be allocated to two single injections of trial product on two separate dosing visits with each of the two insulin degludec/insulin aspart formulations. The trial products will be administered as a subcutaneous injection (under the skin).
Study: NCT04045509

Intervention type: DEVICE
Group type: OTHER
Intervention: Tactile Esthesiometer Prototype
Description: A round plastic nozzle (1.8mm diameter) used as a stimulus for corneal sensation threshold measurement

Intervention type: DEVICE
Group type: OTHER
Intervention: Tactile Esthesiometer Prototype
Description: A round plastic nozzle (1.8mm diameter) used as a stimulus for corneal sensation threshold measurement

Intervention type: DEVICE
Group type: OTHER
Intervention: Cochet Bonnet esthesiometer
Description: A nylon thread (0.12mm diameter) used as a stimulus for corneal sensation threshold measurement
Study: NCT03411538

Intervention type: OTHER
Intervention: Collect data on clinical history
Description: Collect data on clinical history, clinical manifestation, comorbidity, admission data, use of invasive medical intervention, history of antibiotic treatment and antibiotic susceptibility test results
Study: NCT04145934

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADSTEP
Description: ADSTEP is a training program of six weekly one-on-one sessions with a physical therapist intended to reduce falls among people who use a hand-held walking aid, such as a cane or a walker. ADSTEP focuses on training in the use of the walking aid, and includes gait evaluation, walking aid selection and fitting, and progressive task-oriented training with the walking aid.
Study: NCT04713683

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Patent Foramen Ovale Closure
Description: Patients with well-documented embolic stroke of unknown source (ESUS) and a patent foramen ovale (PFO) are indicated for percutaneous closure of PFO. The intervention is performed through the right femoral vein. The interventional cardiologist introduces the sheath and advances the device via inferior vena cava to right atrium. Then, the catheter is passed through the PFO, the device is deployed and the occlusion is achieved. The procedure is performed under fluoroscopy guidance with or without transesophageal echocardiography guidance.
Study: NCT04045509

Intervention type: DEVICE
Group type: OTHER
Intervention: Cochet Bonnet esthesiometer
Description: A nylon thread (0.12mm diameter) used as a stimulus for corneal sensation threshold measurement
Study: NCT02064075

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer's solution
Description: 15-50 ml/kg Lactated-Ringer's solution was given intravenously every day until discharge.
Study: NCT02777580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: Half dose Tenecteplase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 300 mg p.o. initial loading dose. Maintenance dose of 75 mg p.o. once daily. The maintenance dose of Clopidogrel (75 mg p.o. per day) should be continued for 1 year.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary angiography
Description: Coronary angiography followed by PCI or CABG if required, rescue PCI if required

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary PCI
Description: Primary PCI accoring to local standards
Study: NCT02064075

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyethyl starch
Description: 15 ml/kg Lactated-Ringer's and 15-50 ml/kg hydroxyethyl starch solution was given intravenously every day until discharge.
Study: NCT05324488

Intervention type: OTHER
Intervention: No intervention
Description: In this registry no intervention is carried out

Intervention type: OTHER
Intervention: No intervention
Description: In this registry no intervention is carried out

Intervention type: OTHER
Intervention: No intervention
Description: In this registry no intervention is carried out

Intervention type: OTHER
Intervention: No intervention
Description: In this registry no intervention is carried out

Intervention type: OTHER
Intervention: No intervention
Description: In this registry no intervention is carried out

Intervention type: OTHER
Intervention: No intervention
Description: In this registry no intervention is carried out

Intervention type: OTHER
Intervention: No intervention
Description: In this registry no intervention is carried out
Study: NCT05553743

Intervention type: BIOLOGICAL
Intervention: COVID-19 Exposure
Description: Have been or may have been exposed to COVID-19.
Study: NCT00365846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath-1H
Study: NCT03006705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur-gimeracil-oteracil potassium
Description: Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tegafur-gimeracil-oteracil potassium
Description: Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.
Study: NCT04078308

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous Injection of autologous mesenchymal stem cells
Description: Intravenous injection 1 millions of bone-marrow derived autologous Mesenchymal Stem Cells (MSCs) per kg of patient's body weight in each dose, weeks 0 \& 3
Study: NCT03006705

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).
Study: NCT01499147

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fludarabine/busulfan
Description: All patients below age 55, should receive fludarabine/busulfan, and ATG in case of unrelated or mismatched donor, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 \<40%, DLCO\<50%, LVEF\<40, Serum bilirubin \>1.5 mg% or serum transaminases \> 2x nl) and/or specific medical conditions such as preventing a standard myeloablative treatment, as per discussion with the PI.
Study: NCT04078308

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous injection of placebo
Description: Intravenous injection of normal saline (sodium chloride 0.9%)
Study: NCT03641729

Intervention type: OTHER
Group type: OTHER
Intervention: individualized exercise training program
Description: The exercise training program was performed once daily, included 2- to 5-minute warm-up session (stretching, coordination and balance exercises), 10 to 20 minutes of moderate-intensity aerobic exercise using a cycle ergometer, 3 - to 5-sets to ten repetitions of sit-to-stand exercises with a 1-minute rest interval between each set. A cool-down period of 2- to 5-minutes of stretching and breathing exercises was delivered at the end of the exercise session. The aerobic training target zone was set at 50% to 70% of heart rate (HR) reserve.
Study: NCT01721395

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Agave Syrup

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Agave Syrup
Study: NCT01309490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Dose Level: 1 1400 mg po BID Dose Level: 2 1800 mg po BID Dose Level: 3 2200 mg po BID Dose Level: 4 2600 mg po BID Dose Level: 5 3000 mg po BID
Study: NCT04642469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Intravenous administration of Durvalumab

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study: NCT01429506

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sleeve gastrectomy
Description: Sleeve gastrectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intensive medical management
Description: Exenatide 10 mcg BD, Metformin 2-3 gm/day, 800 Kcal diet
Study: NCT03288389

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NTFactor Lipids®
Description: Membrane Lipid Replacement with NTFactor Lipids wafers

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo wafers
Study: NCT00719303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Dietary Intervention
Description: Receive dietary intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compliance Monitoring
Description: Complete daily fat gram and step diaries
Study: NCT02355223

Intervention type: OTHER
Group type: OTHER
Intervention: FAST
Description: See information in arm description
Study: NCT01325441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study: NCT01662999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Study: NCT01325441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study: NCT00719303

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Undergo face-to-face and telephone counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive educational materials

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo physical activity intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00719303

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01499147

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fludarabine/ melphalan
Description: All patients above age 55 or below age 65, should receive fludarabine/melphalan, and ATG, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 \<40%, DLCO\<50%, LVEF\<40, Serum bilirubin \>1.5 mg% or serum transaminases \> 2x nl).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATG
Description: Patients receiving a transplant from a matched unrelated or mismatched related/unrelated donor would receive ATG in the conditioning regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATG
Description: Patients receiving a transplant from a matched unrelated or mismatched related/unrelated donor would receive ATG in the conditioning regimen.
Study: NCT02502474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Staphylococcus aureus carriage
Description: nasal, throat, rectal and groin sampling with swabs. Colonic sampling by colonic biopsy
Study: NCT01960374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: 1, 2 or 3 x 25 mg selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) capsule administered orally as a single dose on Day 1 of the study (total dose 25 mg, 50 mg and 75 mg respectively) with 240 ml of water at room temperature.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: 1, 2 or 3 x 25 mg selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) capsule administered orally as a single dose on Day 1 of the study (total dose 25 mg, 50 mg and 75 mg respectively) with 240 ml of water at room temperature.
Study: NCT03682341

Intervention type: GENETIC
Intervention: endometriosis
Description: patients with or without ovarian endometriosis

Intervention type: GENETIC
Intervention: endometriosis
Description: patients with or without ovarian endometriosis
Study: NCT03909620

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography of chest
Description: Eligible subjects will undergo a single round of LDCT screening. The LDCT will be considered as positive if a solid nodule or part-solid nodule of size ≥6 mm or non-solid nodule of size ≥20 mm is identified. Evaluation of positive nodules will be performed as per existing standard recommendations
Study: NCT04504240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine 20 MG
Description: Famotidine; tablet Famotac 20mg oral form.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine 20 MG
Description: Famotidine; tablet Famotac 20mg oral form.
Study: NCT02834026

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cicloergometry training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Cicloergometry training
Study: NCT00820586

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mononuclear bone marrow derived cells
Description: Direct intramyocardial percutaneous delivery of autologous bone marrow-derived total mononuclear cells or selected CD34+ cells

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mononuclear bone marrow derived cells
Description: Direct intramyocardial percutaneous delivery of autologous bone marrow-derived total mononuclear cells or selected CD34+ cells
Study: NCT01703975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training in pairs (Dyad training)
Study: NCT03023956

Intervention type: PROCEDURE
Intervention: Locking plates were used for proximal humeral fractures.

Intervention type: PROCEDURE
Intervention: Locking plates were used for proximal humeral fractures.
Study: NCT00614250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE0657
Description: capsules once a day at bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE0657
Description: capsules once a day at bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE0657
Description: capsules once a day at bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE0657
Description: capsules once a day at bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: capsules once a day at bedtime
Study: NCT04185493

Intervention type: DIAGNOSTIC_TEST
Intervention: CCTA
Description: 128-multislice CT coronary angiography and complex atherosclerotic plaque analysis with the use of CT imaging post-processing techniques.
Study: NCT03950089

Intervention type: DEVICE
Intervention: Optical Coherence Tomography Angiography (OCT-A)
Description: Optical Coherence Tomography Angiography (OCT-A) images were acquired using an Spectral Domain Optical Coherence Tomography device (Cirrus High Definition OCT Model 5000 with Angioplex; Carl Zeiss Meditec, Dublin, California, USA). With an acquisition speed of 68,000 A-Scan per second, the OCT Microangiography Complex algorithm provided OCT-A information for three-dimensional (3D) flow reconstruction. At each visit, each subject underwent a 3 x 3 millimeter (mm) macular 3D cube acquisition in both eyes. FastTrac continuous eye tracking technology was employed to control for eye movements and minimize motion artefacts.

Intervention type: DEVICE
Intervention: Optical Coherence Tomography Angiography (OCT-A)
Description: Optical Coherence Tomography Angiography (OCT-A) images were acquired using an Spectral Domain Optical Coherence Tomography device (Cirrus High Definition OCT Model 5000 with Angioplex; Carl Zeiss Meditec, Dublin, California, USA). With an acquisition speed of 68,000 A-Scan per second, the OCT Microangiography Complex algorithm provided OCT-A information for three-dimensional (3D) flow reconstruction. At each visit, each subject underwent a 3 x 3 millimeter (mm) macular 3D cube acquisition in both eyes. FastTrac continuous eye tracking technology was employed to control for eye movements and minimize motion artefacts.
Study: NCT03968172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EBBC programme
Description: Web-based behavioural lifestyle intervention that provides patients with coordinated information based on their existing health beliefs, interests, etc. In the programme, techniques and exercises will be taught in sequentially active interactive learning units (simulated dialogues) and followed-up with email and SMS reminders in the second study year. The following topics will be focused on:~1. Diagnosis and disease progression~2. Support in disease processing~3. Techniques for coping with stress and depressive symptoms as well as developing positive emotions~4. Optimisation of dietary behaviour~5. Optimisation of physical activity behaviour~6. Sleep hygiene and methods for dealing with insomnia.~The programme will accompany each patient with information material and e-mail reminders over a period of 12 months with initial 2-3 weekly tasks, later only weekly reminders and inputs every 2 weeks. All in all, the intervention programme will consist of 16 modules.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group programme
Description: Web-based information platform with optimized standard care compiled from information material of the German Multiple Sclerosis Society (DMSG). Information will be provided in sequentially activated modules over a period of 12 months, covering the following topics:~1. Disease progression~2. Invisible symptoms of multiple sclerosis~3. Symptomatic therapy~4. Immunotherapy decision support~5. Coping strategies~6. Autonomy~7. Fatigue~8. Quality of life~9. Physical activity~10. Nutritional behaviour~In addition, a reminder system with neutral e-mail reminders will be used to promote the use of the programme.
Study: NCT00958334

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Proellex®
Description: 25 mg daily (two 12.5 mg capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex®
Description: 25 mg daily (two 12.5 mg capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex®
Description: 25 mg daily (two 12.5 mg capsules)
Study: NCT01095315

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lateral positioning
Description: the lateral position was maintained for 6 min after spinal injection before patients were turned to the supine position
Study: NCT02816450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water Intake

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water Intake
Study: NCT00247195

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally Congruent Assessment and Treatment
Description: Referral, engagement, and treatment is done following the cultural formulation model in DSM-IV in which patients' views and expectations about depression treatment are included in the assessment and treatment process.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Culturally Congruent Assessment and Treatment
Description: Referral, engagement, and treatment is done following the cultural formulation model in DSM-IV in which patients' views and expectations about depression treatment are included in the assessment and treatment process.
Study: NCT00144534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRA (Tocilizumab)
Description: 8mg/kg/4 weeks
Study: NCT03251430

Intervention type: PROCEDURE
Intervention: gastrectomy
Description: Distal gastrectomy, Total gastrectomy

Intervention type: PROCEDURE
Intervention: gastrectomy
Description: Distal gastrectomy, Total gastrectomy
Study: NCT01971060

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: surgery utilizing V-Loc suture
Description: V-Loc suture will be utilized in the repair of the uterus following removal of fibroid tumors. a second look laparoscopy will be done on all subjects to evaluate scar tissue formation.
Study: NCT02219620

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music, Imagery, Movement
Description: Implementation of music, art and imagery activation, and movement in group modality

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Control
Description: social conversational group facilitated by care counselor
Study: NCT05181566

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total hip replacement arthroplasty using modular dual mobility cup
Description: In a total hip replacement (also called total hip arthroplasty), the damaged bone and cartilage is removed and replaced with prosthetic components
Study: NCT05040529

Intervention type: PROCEDURE
Intervention: pure laparoscopic donor hepatectomy
Description: pure laparoscopic donor hepatectomy: patients who underwent pure laparoscopic right or right extended hepatectomy for liver donation at gangnam severance hospital

Intervention type: PROCEDURE
Intervention: conventional open donor hepatectomy
Description: conventional open donor hepatectomy: patients who underwent conventional right or right extended hepatectomy for liver donation at gangnam severance hospital
Study: NCT01783665

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: home exercise program
Study: NCT02205450

Intervention type: DRUG
Intervention: Recombinant Somatropin
Study: NCT02628587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic clopidogrel
Description: Comparison of different brands of clopidogrel:~\*Clopidogrel (generic) 300mg orally single dose on day 0. Later, clopidogrel 75mg orally single dose on days 1, 2 and 3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patent clopidogrel
Description: Comparison of different brands of clopidogrel:~\*Clopidogrel (Plavix) 300mg orally single dose on day 0. Later, clopidogrel 75mg orally single dose on days 1, 2 and 3.